文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

新英格兰地区SARS-CoV-2奥密克戎BA.2亚分支严重程度的估计

Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England.
PubMed 文献 · JAMA Netw Open · 2022-10-03
一句话结论经熵平衡校正混杂后,奥密克戎BA.2亚分支的30天死亡、住院、ICU入住及有创通气风险均显著低于德尔塔和原始奥密克戎变异株。

这项回顾性队列研究在新英格兰一个多中心住院与门诊系统中纳入2020年3月3日至2022年6月20日确诊的102315例COVID-19病例,采用熵平衡法校正混杂,比较德尔塔、原始奥密克戎与奥密克戎BA.2亚分支的30天死亡、住院、ICU入住及有创通气风险。30天死亡率分别为德尔塔0.7%、原始奥密克戎0.4%、BA.2 0.3%;校正后德尔塔相对BA.2的死亡比值比为2.07(95%CI 1.04-4.10),原始奥密克戎相对BA.2为2.20(95%CI 1.56-3.11)。所有结局中BA.2的严重程度均显著低于德尔塔和原始奥密克戎。作者认为,在考虑治疗、疫苗接种和既往感染等因素后,SARS-CoV-2的严重程度似乎正在减弱。

要点

  • 校正混杂后,德尔塔相对BA.2亚分支的30天死亡OR为2.07(95%CI 1.04-4.10),原始奥密克戎相对BA.2为2.20(95%CI 1.56-3.11)。
  • 粗死亡率:德尔塔0.7%、原始奥密克戎0.4%、奥密克戎BA.2 0.3%。
  • 所有结局(死亡、住院、ICU入住、有创通气)中,BA.2亚分支均显著轻于原始奥密克戎和德尔塔。
  • 研究采用熵平衡法校正多种与SARS-CoV-2结局相关的混杂因素。
  • 作者认为,在考虑治疗、疫苗接种和既往感染等因素后,SARS-CoV-2的严重程度似乎正在减弱。

适用人群与场景

  • 新英格兰一个多中心住院与门诊系统中2020年3月3日至2022年6月20日确诊的COVID-19病例,共102315例(平均[SD]年龄44.2[21.6]岁;女性63482例[62.0%])。
  • 排除发生在与各变异株相关的预设时间窗之外的病例,或COVID-19前在Mass General Brigham系统中纵向数据极少的病例。

研究设计与关键结果

  • 研究类型:回顾性队列研究,采用熵平衡法校正混杂;单中心或多中心:原文写明为一个多中心住院与门诊系统;样本量102315例。
  • 暴露分组:德尔塔(B.1.617.2)20770例、原始奥密克戎(B.1.1.529)52605例、奥密克戎BA.2亚分支28940例。
  • 主要终点(分析前预设)为30天死亡风险:德尔塔0.7%、原始奥密克戎0.4%、奥密克戎BA.2 0.3%。
  • 校正后30天死亡:德尔塔相对BA.2的OR为2.07(95%CI 1.04-4.10);原始奥密克戎相对BA.2的OR为2.20(95%CI 1.56-3.11)。
  • 次要终点包括住院、有创通气、ICU入住风险;所有结局中BA.2亚分支均显著轻于原始奥密克戎和德尔塔变异株。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在考虑治疗、疫苗接种和既往感染等因素后,SARS-CoV-2的严重程度似乎正在减弱。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The SARS-CoV-2 Omicron subvariant, BA.2, may be less severe than previous variants; however, confounding factors make interpreting the intrinsic severity challenging.

OBJECTIVE: To compare the adjusted risks of mortality, hospitalization, intensive care unit admission, and invasive ventilation between the BA.2 subvariant and the Omicron and Delta variants, after accounting for multiple confounders.

DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective cohort study that applied an entropy balancing approach. Patients in a multicenter inpatient and outpatient system in New England with COVID-19 between March 3, 2020, and June 20, 2022, were identified.

EXPOSURES: Cases were assigned as being exposed to the Delta (B.1.617.2) variant, the Omicron (B.1.1.529) variant, or the Omicron BA.2 lineage subvariants.

MAIN OUTCOMES AND MEASURES: The primary study outcome planned before analysis was risk of 30-day mortality. Secondary outcomes included the risks of hospitalization, invasive ventilation, and intensive care unit admissions.

RESULTS: Of 102 315 confirmed COVID-19 cases (mean [SD] age, 44.2 [21.6] years; 63 482 women [62.0%]), 20 770 were labeled as Delta variants, 52 605 were labeled as the Omicron B.1.1.529 variant, and 28 940 were labeled as Omicron BA.2 subvariants. Patient cases were excluded if they occurred outside the prespecified temporal windows associated with the variants or had minimal longitudinal data in the Mass General Brigham system before COVID-19. Mortality rates were 0.7% for Delta (B.1.617.2), 0.4% for Omicron (B.1.1.529), and 0.3% for Omicron (BA.2). The adjusted odds ratio of mortality from the Delta variant compared with the Omicron BA.2 subvariants was 2.07 (95% CI, 1.04-4.10) and that of the original Omicron variant compared with the Omicron BA.2 subvariant was 2.20 (95% CI, 1.56-3.11). For all outcomes, the Omicron BA.2 subvariants were significantly less severe than that of the Omicron and Delta variants.

CONCLUSIONS AND RELEVANCE: In this cohort study, after having accounted for a variety of confounding factors associated with SARS-CoV-2 outcomes, the Omicron BA.2 subvariant was found to be intrinsically less severe than both the Delta and Omicron variants. With respect to these variants, the severity profile of SARS-CoV-2 appears to be diminishing after taking into account various factors including therapeutics, vaccinations, and prior infections.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Strasser ZH, Greifer N, Hadavand A, et al. Estimates of SARS-CoV-2 Omicron BA.2 Subvariant Severity in New England. JAMA Netw Open. 2022. PMID: 36282501. doi:10.1001/jamanetworkopen.2022.38354

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。